

AMENDMENTS TO THE CLAIMS

1. (Previously presented) A method for administering daptomycin, comprising the step of administering to a human patient in need thereof a therapeutically effective amount of daptomycin in a dose of at least 3 mg/kg of daptomycin at a dosage interval that minimizes skeletal muscle toxicity, wherein the daptomycin dose is repeatedly administered at a dosage interval of once every 48 hours to once weekly.

2-6. (Cancelled)

7. (Previously presented) The method according to claim 1, wherein the dose is 3 to 12 mg/kg.

8. (Original) The method according to claim 7, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

9. (Previously presented) The method according to claim 1, wherein the dose is 10 to 25 mg/kg.

10. (Original) The method according to claim 9, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

11. (Previously presented) The method according to claim 1, wherein an antibiotic other than daptomycin is co-administered with the lipopeptide antibiotic.

12. (Canceled)

13. (Original) The method according to claim 11, wherein said antibiotic is selected from the group consisting of penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, sulfonamides, trimethoprim and its combinations, pyrimethamine, synthetic antibacterials, nitrofurans, methenamine mandelate, methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone and viomycin.

14. (Original) The method according to claim 11, wherein said antibiotic is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin and teicoplanin.

15. (Original) The method according to claim 11, wherein said administering is via oral, subcutaneous or intravenous administration.

16-25 (Canceled)

26. (Previously presented) The method according to claim 1, wherein said administering is via oral, subcutaneous or intravenous administration.

Claims 27-33 (Canceled)

34. (New) The method according to claim 1 wherein the daptomycin dose is repeatedly administered at a dosage interval of once every 48 hours to once every 96 hours.

35. (New) The method according to claim 34 wherein the dosage interval is once every 72 hours.

36. (New) The method according to claim 34 wherein the dosage interval is once every 96 hours.

37. (New) The method according to claim 34, wherein the dose is 3 to 12 mg/kg.

38. (New) The method according to claim 37, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

39. (New) The method according to claim 37, wherein the dose is 4, 6, 8 or 10 mg/kg.

40. (New) The method according to claim 37 wherein the dose is 4 mg/kg.

41. (New) The method according to claim 37 wherein the dose is 6 mg/kg.

42. (New) The method according to claim 34 wherein the dose is 25 to 75 mg/kg.

43. (New) The method according to claim 42 wherein the dose is 25, 50 or 75 mg/kg.

44. (New) The method according to claim 34, wherein the dose is 10 to 25 mg/kg.

45. (New) The method according to claim 44, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

46. (New) The method according to claim 34, wherein said administering is via oral, subcutaneous or intravenous administration.

47. (New) The method according to claim 34, wherein the daptomycin is administered for 3 days to 6 months.

48. (New) The method according to claim 34, wherein the daptomycin is administered for 7 to 28 days.

49. (New) The method according to claim 34, wherein the daptomycin is administered for 7 to 14 days.

50. (New) A method for treating or eradicating a bacterial infection in a human patient in need thereof, comprising the step of administering a therapeutically effective amount of daptomycin in a dose of 3 to 75 mg/kg to the patient at a dosage interval that minimizes skeletal muscle toxicity, wherein the daptomycin dose is repeatedly administered at a dosage interval of once every 48 hours to once weekly, until said bacterial infection is treated or eradicated.

51. (New) The method according to claim 34 wherein the dosage interval is once every 48 hours to once every 96 hours.

52. (New) The method according to claim 51 wherein the dosage interval is once every 48 hours.

53. (New) The method according to claim 51 wherein the dosage interval is once every 72 hours.

54. (New) The method according to claim 51 wherein the dosage interval is once every 96 hours.

55. (New) The method according to claim 50, wherein the dose is 3 to 12 mg/kg.

56. (New) The method according to claim 50, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

57. (New) The method according to claim 50, wherein the dose is 25 to 75 mg/kg.

58. (New) The method according to claim 57 wherein the dose is 25, 50 or 75 mg/kg.

59. (New) The method according to claim 50, wherein the dose is 10 to 25 mg/kg.

60. (New) The method according to claim 59, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

61. (New) The method according to claim 60, wherein the dose is 4 mg/kg.

62. (New) The method according to claim 60, wherein the dose is 6 mg/kg.

63. (New) The method according to claim 50, wherein the daptomycin is administered for 3 days to 6 months.

64. (New) The method according to claim 50, wherein the daptomycin is administered for 7 to 28 days.

65. (New) The method according to claim 50, wherein the daptomycin is administered for 7 to 14 days.

66. (New) The method according to claim 61, wherein the daptomycin is administered for 7 to 28 days.

67. (New) The method according to claim 68, wherein the daptomycin is administered for 7 to 14 days.

68. (New) The method according to claim 62, wherein the daptomycin is administered for 7 to 14 days.

69. (New) The method according to claim 68, wherein the daptomycin is administered for 7 to 28 days.

70. (New) A method for administering daptomycin, comprising the step of administering to a human patient in need thereof a therapeutically effective amount of daptomycin in a dose of at least 3 mg/kg of daptomycin at a dosage interval that minimizes skeletal muscle toxicity, wherein the dose is repeatedly administered at a dosage interval of once every 48 hours.

71. (New) The method according to claim 70, wherein the dose is 3 to 12 mg/kg.

72. (New) The method according to claim 71, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

73. (New) The method according to claim 71, wherein the dose is 4, 6, 8 or 10 mg/kg

74. (New) The method according to claim 71 wherein the dose is 4 mg/kg.

75. (New) The method according to claim 71 wherein the dose is 6 mg/kg.

76. (New) The method according to claim 71 wherein the dose is 8 mg/kg.

77. (New) The method according to claim 70, wherein said administering is via oral, subcutaneous or intravenous administration.

78. (New) The method according to claim 70, wherein the daptomycin is administered for 3 days to 6 months.

79. (New) The method according to claim 70, wherein the daptomycin is administered for 7 to 28 days.

80. (New) The method according to claim 70, wherein the daptomycin is administered for 7 to 14 days.